Ranélate de strontium : une nouvelle approche de l'ostéoporose post-ménopausique

Abstract

Strontium ranelate is a novel antiosteoporotic agent that decreases bone resorption while stimulating bone formation. Two large phase III randomized, placebo-controlled studies have been performed to document its effects on the risks of vertebral and non vertebral fractures in postmenopausal women. In 1649 osteoporotic women with prevalent vertebral fracture enrolled in the SOTI study, strontium ranelate was proven efficient in reducing the risk of incident vertebral fractures and improving quality of life. In 5091 osteoporotic women enrolled in the TROPOS study, a significant reduction was observed in the risk of experiencing a new non-vertebral fracture and major osteoporotic fractures over 3 years. The incidence of hip fracture was significantly decreased in a subgroup of 1977 osteoporotic patients aged 74 years or over. In the TROPOS study, a significant reduction over 3 years of the relative risk of first vertebral fracture was demonstrated in women without prevalent vertebral fracture. Furthermore, strontium ranelate was proven able to decrease the relative risk of vertebral and non vertebral fractures in women aged 80 years and over. In osteopenic patients without prevalent fracture, strontium ranelate was shown to reduce the relative risk of vertebral fracture. Strontium ranelate demonstrated in these studies a very good safety profile.